Veradigm Agreement with Lash Group Expands Patient Solutions Platform

Veradigm®, a leading provider of data and technology solutions and a business unit of Allscripts Healthcare Solutions announced an agreement with Lash Group, a patient support services business, and a part of AmerisourceBergen.

This relationship will enable specialty medications, supported by Lash Group, to be available for management within the Veradigm AccelRx™ platform, which streamlines the specialty enrollment process for users of Veradigm, Allscripts’ and other electronic health record (EHR) software vendors.

Through this collaboration, Veradigm and Lash Group can deliver a frictionless solution that will drive efficiency, resulting in a streamlined process and increased speed-to-therapy. Veradigm AccelRx™ delivers a unique breakthrough solution that is helping to streamline specialty medication management for medical clinics and practices across the country.

Veradigm is an integrated data systems and services company that combines data-driven clinical insights with actionable tools to help healthcare stakeholders improve the quality, efficiency, and value of healthcare delivery— including biopharma, health plans, healthcare providers, health technology partners, and most importantly, the patients they serve.

Lash Group strategically designs, delivers and continuously improves patient access and adherence programs to ensure patients receive the best possible care, while strengthening product performance at every stage of its life cycle.

AmerisourceBergen’s technology platform has supported the Lash Group. Lash Group’s Fusion combines dozens of best-in-class technologies with workflows that are customized for patient support services. It also features a proprietary, advanced data model that enables Lash Group to provide a personalized and seamless experience for patients, providers and manufacturers — ultimately improving patient access to life saving medications and enhancing patient engagement and outcomes.


Takeaway: this strategic relationship with Lash Group is a major step in Veradigm’s progress toward expediting the specialty drug review, approval and fulfillment process